NEW YORK - The emergence of the omicron varianthas renewed fears of the novel coronavirus developing mutations that would allow it to evade existing vaccines, but the companies Pfizer and BioNTech are currently running tests in response to the rapidly spreading variant with data available in the coming weeks."Pfizer and BioNTech are remaining vigilant and constantly conducting surveillance efforts focused on monitoring for emerging variants that potentially escape protection from our vaccine," a spokesperson for Pfizer told FOX Television Stations. "We are beginning to run neutralization tests on the new Omicron variant of concern and expect to have initial data in the coming weeks."BioNTech CEO Ugur Sahin told news organization Reuters in.